AMG-510, an inhibitor targeting KRAS G12C, which accounts for 13% of KRAS mutant NSCLC [140], is currently under investigation in a Phase I/II clinical trial of advanced KRAS mutant solid tumors. Here, KRAS is linked to non-small cell lung carcinoma.